Sign up for our daily briefing

Make your busy days simpler with the Axios AM and PM newsletters. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to the Axios Closer newsletter for insights into the day’s business news and trends and why they matter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios Pro Rata

Dive into the world of dealmakers across VC, PE and M&A with Axios Pro Rata. Delivered daily to your inbox by Dan Primack and Kia Kokalitcheva.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with the Axios Sports newsletter. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with the Axios Des Moines newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with the Axios Tampa Bay newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Nashville news?

Get a daily digest of the most important stories affecting your hometown with the Axios Nashville newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Columbus news?

Get a daily digest of the most important stories affecting your hometown with the Axios Columbus newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Dallas news?

Get a daily digest of the most important stories affecting your hometown with the Axios Dallas newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Austin news?

Get a daily digest of the most important stories affecting your hometown with the Axios Austin newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Atlanta news?

Get a daily digest of the most important stories affecting your hometown with the Axios Atlanta newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Philadelphia news?

Get a daily digest of the most important stories affecting your hometown with the Axios Philadelphia newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Chicago news?

Get a daily digest of the most important stories affecting your hometown with the Axios Chicago newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top DC news?

Get a daily digest of the most important stories affecting your hometown with the Axios DC newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

A medical illustration of Candida auris from the CDC's "Antibiotic Resistance Threats in the United States, 2019." Credit: Stephanie Rossow/CDC

CDC officials are concerned about a strain of the Candida auris fungus that's resistant to all drugs and appears to have spread in small clusters in health care settings, rather than in individuals who had taken antifungals.

Why it matters: "The concern is that it could spread to any of the patients who are at high risk, not just the ones who've been treated before — and that the population who could acquire these potentially untreatable infections could be much larger," Meghan Lyman, medical officer in the CDC's Mycotic Diseases Branch, tells Axios.

Background: There are only three main classes of drugs to fight invasive fungal infections: azoles, polyenes and echinocandins. There has been growing evidence of C. auris becoming resistant to one or two of these drugs, with echinocandins usually remaining effective.

  • But the latest clusters were resistant to all three.
  • The fact that C. auris can colonize skin or surfaces, and often doesn't respond to traditional ammonia cleaners, has caused some health care facilities to rip out entire units after infection. The EPA recently issued a list of approved cleaning agents to try and combat this.
  • However, there had only been a few isolated cases of known pan-resistant C. auris in the U.S. before 2021, all in patients who had susceptible strains and had developed resistance after taking antifungals, Lyman says.

What's happening: As detailed in the CDC's MMWR report Thursday, small, independent clusters of pan-resistant C. auris infections were found from January to April this year: three in D.C. (out of 101 C. auris cases) and two in Texas (out of 22 cases).

  • "These clusters are the first time where we're really concerned that it's spreading," Lyman says, as none of the patients had been exposed to echinocandin before.
  • "It's most likely spread through contaminated health care surfaces, " she says, which can include anything from beds, to mobile equipment, to shared PPE, to the hands from a health care worker if not properly sanitized.
  • Plus, not only does the CDC believe C. auris is underreported. But the rising number of known infections overall means there's a "greater chance of having more resistance pop up," Lyman says.

What's next: If a hospital, nursing home or long-term care facility suspects C. auris, they should reach out to their local health department for guidance, Lyman says.

  • While these pan-resistant infections are untreatable with the three classes of antifungals, there are investigational drugs looking at combination therapies and a new class of antifungals is in the pipeline, which could be "very exciting," she adds.

Go deeper: The growing threat of drug-resistant, invasive fungi

Go deeper

Jul 22, 2021 - Health

COVID cases are up 55% across the U.S.

Expand chart
Data: CSSE Johns Hopkins University; Note: Rhode Island and Iowa data is from CDC and from July 12-July 19; Map: Axios Visuals

Coronavirus infections are rising dramatically all over the U.S. as the highly contagious Delta variant spreads.

The big picture: Some “breakthrough” infections are happening to vaccinated people, but this rising tide of cases and hospitalizations is mainly a threat to those who aren’t vaccinated. And in some parts of the country, most people aren’t vaccinated — so the virus can still do serious damage.

The hard math behind America's labor shortage

Data: Bureau of Labor Statistics, Congressional Budget Office; Chart: Axios Visuals

Yes, the pandemic has created unusual temporary labor market dynamics. But in the bigger picture, the 2010s were a golden age for companies seeking cheap labor. The 2020s are not.

The big picture: In the 2010s, the massive millennial generation was entering the workforce, the massive baby bo0m generation was still hard at work, and there was a multi-year hangover from the deep recession caused by the global financial crisis.

Advocates fret Roe v. Wade's 49th anniversary could be its last

Photo: Leigh Vogel/Getty Images for Women's March Inc

As Saturday marks the 49th anniversary of Roe v. Wade, the Supreme Court's landmark decision that legalized abortion access in the U.S., advocates warn the ruling is "more at risk now than ever."

The big picture: The Supreme Court in December heard a challenge to a Mississippi 15-week abortion ban that could throw Roe's survival into question, or at least narrow its scope.

You’ve caught up. Now what?

Sign up for Mike Allen’s daily Axios AM and PM newsletters to get smarter, faster on the news that matters.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!